Significant recent representative matters include:
Represented numerous pharmaceutical companies in defending their patents on multi-billion and multi-million dollar drug products, including:
Ms. Rupert frequently speaks and writes about current patent issues. Recent representative publications and engagements include:
Paul Hastings’ IP Litigation Practice Recognized as an IP Powerhouse with 25 Rankings by IAM Patent 1000 and Legal 500 US
June 12, 2020
Paul Hastings Soars in 2011 Edition of Legal 500 US
June 01, 2011
What Drug Companies Should Be Thinking About After the U.S. - China Trade Deal
January 23, 2020
Keeping It Done When It’s Over: New Rules for Submitting Generic/Biosimilar Settlements to DOJ and FTC
August 12, 2019
Federal Circuit Issues Expansive Ruling in Upholding Jurisdiction over Mylan in Delaware
March 18, 2016
District of Delaware Finds Specific Jurisdiction Exists Over an ANDA Filer in the Context of a Hatch-Waxman Case
November 06, 2014
FDA Issues Draft Guidance on Reference Product Exclusivity for Biologics
August 07, 2014
District of New Jersey Prevents Generic Challenger from Using Claim Construction as a Backdoor to Introduce Barred Invalidity Defense
June 16, 2014
Limitation on Future Patent Protection for Biosimilars?
August 06, 2012
A Sign of Future Biosimilars Litigation?
November 21, 2011
Recognized by Managing IP as the Life Sciences IP Litigation Firm of the Year
Paul Hastings was was recognized by Managing IP at their Americas Awards, which honored individuals and companies behind the most innovative and challenging IP work of the past year, as well as those driving the international IP market.
The firm was recognized as Life Sciences IP Litigation Firm of the Year in the United States.
April 05, 2019
Recognized as Post-Grant Firm of the Year by IAM Magazine
Paul Hastings was recognized as the Post-Grant Firm of the Year at Intellectual Asset Management's inaugural Global IP Awards. The award recognizes the achievements of the firm's Patent Trial and Appeal Board (PTAB) Team, which practices before the US Patent & Trial Office. Over the past year, the team's accomplishments include numerous post-grant proceeding victories for technology and life sciences clients - four of which were affirmed by the Court of Appeals for the Federal Circuit.
January 30, 2019
Recognized among ManagingIP's "Top 250 Women in IP"
Melanie Rupert was named one of the “Top 250 Women in IP” by Managing
September 30, 2014
Recognized among ManagingIP's "IP Stars"
Bruce Wexler, Chris Kennerly, Melanie Rupert, Joseph O'Malley, Gerald Flattmann, and Jeff Randall, and were named IP Stars by Managing Intellectual Property magazine. Nationwide, the firm's Intellectual Property practice was ranked in the Bio/Life Sciences, Copyright and Patent Contentious categories.
In New York, the firm's IP practice was ranked Highly Recommended in the Patent Contentious category and in California, the IP practice was ranked Recommended in the Copyright and Patent Contentious categories.
April 29, 2014
Nominated for the Legal Media Group's LMG Life Science Awards
The firm was nominated for the Legal Media Group's 2013 LMG Life Sciences awards in the categories of “Litigation Team of the Year” and “(General) Patent Litigation: Firm of the Year."
August 12, 2013
Recognized as IP Pharma Team of the Year by Intellectual Property Magazine
Intellectual Property Magazine recognized Paul Hastings' IP Pharmaceutical Team as the Pharmaceutical Team of the Year.
November 30, 2010